Martin F Fromm

List of Publications by Year
in descending order

146 papers	12,126 citations	28190 55 h-index	26548 107 g-index
150 all docs	150 docs citations	150 times ranked	10550 citing authors

#	Article	IF	Citations
1	Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Cardiovascular Diabetology, 2022, 21, 4.	2.7	4
2	Inconsistencies and Ambiguities in Liver-Disease-Related Contraindicationsâ€"A Systematic Analysis of SmPCs/PI of Major Drug Markets. Journal of Clinical Medicine, 2022, 11, 1933.	1.0	3
3	L-Arginine and Cardioactive Arginine Derivatives as Substrates and Inhibitors of Human and Mouse NaCT/Nact. Metabolites, 2022, 12, 273.	1.3	2
4	Renal Transporterâ€Mediated Drugâ€Biomarker Interactions of the Endogenous Substrates Creatinine and N¹â€Methylnicotinamide: A PBPK Modeling Approach. Clinical Pharmacology and Therapeutics, 2022, 112, 687-698.	2.3	9
5	Exposure of Fexofenadine, but Not Pseudoephedrine, Is Markedly Decreased by Green Tea Extract in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2022, 112, 627-634.	2.3	4
6	Comprehensibility of Contraindications in German, UK and US Summaries of Product Characteristics/Prescribing Informationâ€"A Comparative Qualitative and Quantitative Analysis. Journal of Clinical Medicine, 2022, 11, 4167.	1.0	1
7	Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters. Pharmaceutics, 2021, 13, 369.	2.0	14
8	Transport of Drugs and Endogenous Compounds Mediated by Human OCT1: Studies in Single- and Double-Transfected Cell Models. Frontiers in Pharmacology, 2021, 12, 662535.	1.6	11
9	The CredibleMedsÂ® list: usage of QT interval prolonging drugs in Germany and discordances with prescribing information. British Journal of Clinical Pharmacology, 2021, , .	1.1	5
10	The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer Agents. Journal of Clinical Oncology, 2021, 39, 1983-1994.	0.8	37
11	Medication Errors During Treatment with New Oral Anticancer Agents: Consequences for Clinical Practice Based on the AMBORA Study. Clinical Pharmacology and Therapeutics, 2021, 110, 1075-1086.	2.3	12
12	An Easily Expandable Multi-Drug LC-MS Assay for the Simultaneous Quantification of 57 Oral Antitumor Drugs in Human Plasma. Cancers, 2021, 13, 6329.	1.7	9
13	Drugs linked to plasma homoarginine in chronic kidney disease patientsâ€"a cross-sectional analysis of the German Chronic Kidney Disease cohort. Nephrology Dialysis Transplantation, 2020, 35, 1187-1195.	0.4	4
14	Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease. Pharmacological Reviews, 2020, 72, 343-379.	7.1	100
15	Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine. Clinical Pharmacokinetics, 2020, 59, 1627-1639.	1.6	28
16	Regiospecific Introduction of Halogens on the 2-Aminobiphenyl Subunit Leading to Highly Potent and Selective M3 Muscarinic Acetylcholine Receptor Antagonists and Weak Inverse Agonists. Journal of Medicinal Chemistry, 2020, 63, 4349-4369.	2.9	5
17	Vectorial transport of the arginine derivatives asymmetric dimethylarginine (ADMA) and l-homoarginine by OATP4C1 and P-glycoprotein studied in double-transfected MDCK cells. Amino Acids, 2020, 52, 975-985.	1.2	5
18	Trimethylamine-N-oxide (TMAO) determined by LC-MS/MS: distribution and correlates in the population-based PopGen cohort. Clinical Chemistry and Laboratory Medicine, 2020, 58, 733-740.	1.4	24

#	Article	IF	Citations
19	Effects of single green tea ingestion on pharmacokinetics of nadolol in healthy volunteers. British Journal of Clinical Pharmacology, 2020, 86, 2314-2318.	1.1	14
20	Prostaglandin E2 stimulates the epithelial sodium channel (ENaC) in cultured mouse cortical collecting duct cells in an autocrine manner. Journal of General Physiology, 2020, 152, .	0.9	13
21	Establishment of reference values for the lysine acetylation marker NÉ›-acetyllysine in small volume human plasma samples by a multi-target LCâ€“MS/MS method. Amino Acids, 2019, 51, 1259-1271.	1.2	7
22	Interplay of the Organic Cation Transporters OCT1 and OCT2 with the Apically Localized Export Protein MATE1 for the Polarized Transport of Trospium. Molecular Pharmaceutics, 2019, 16, 510-517.	2.3	14
23	The renal transport protein OATP4C1 mediates uptake of the uremic toxin asymmetric dimethylarginine (ADMA) and efflux of cardioprotective L-homoarginine. PLoS ONE, 2019, 14, e0213747.	1.1	17
24	Clinical Aspects of Transporterâ€Mediated Drugâ€“Drug Interactions. Clinical Pharmacology and Therapeutics, 2019, 105, 1386-1394.	2.3	88
25	New Oral Anti-Cancer Drugs and Medication Safety. Deutsches Ärzteblatt International, 2019, 116, 775-782.	0.6	26
26	Role of (â^')-epigallocatechin gallate in the pharmacokinetic interaction between nadolol and green tea in healthy volunteers. European Journal of Clinical Pharmacology, 2018, 74, 775-783.	0.8	43
27	Biomarkers for In Vivo Assessment of Transporter Function. Pharmacological Reviews, 2018, 70, 246-277.	7.1	59
28	Dose adjustment of cisplatin, etoposide, and ifosfamide according to kidney function: a retrospective analysis and implications for medication safety. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 219-229.	1.4	3
29	Analysis of naturally occurring mutations in the human uptake transporter NaCT important for bone and brain development and energy metabolism. Scientific Reports, 2018, 8, 11330.	1.6	24
30	Importance of OCT2 and MATE1 for the Cimetidineâ€“Metformin Interaction: Insights from Investigations of Polarized Transport in Single- And Double-Transfected MDCK Cells with a Focus on Perpetrator Disposition. Molecular Pharmaceutics, 2018, 15, 3425-3433.	2.3	23
31	Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate). PLoS ONE, 2018, 13, e0202706.	1.1	11
32	The human longevity gene homolog INDY and interleukinâ€6 interact in hepatic lipid metabolism. Hepatology, 2017, 66, 616-630.	3.6	55
33	Contribution of MATE1 to Renal Secretion of the NMDA Receptor Antagonist Memantine. Molecular Pharmaceutics, 2017, 14, 2991-2998.	2.3	22
34	The prognostic biomarker L-homoarginine is a substrate of the cationic amino acid transporters CAT1, CAT2A and CAT2B. Scientific Reports, 2017, 7, 4767.	1.6	27
35	Anticholinergic burden and cognitive function in a large German cohort of hospitalized geriatric patients. PLoS ONE, 2017, 12, e0171353.	1.1	50
36	Assays for Analyzing the Role of Transport Proteins in the Uptake and the Vectorial Transport of Substances Affecting Cell Viability. Methods in Molecular Biology, 2017, 1601, 123-135.	0.4	5

#	Article	IF	Citations
37	Development of a Standardized Rating Tool for Drug Alerts to Reduce Information Overload. Methods of Information in Medicine, 2016, 55, 507-515.	0.7	8
38	Analysis of amino acid residues in the predicted transmembrane pore influencing transport kinetics of the hepatic drug transporter organic anion transporting polypeptide 1B1 (OATP1B1). Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 2894-2902.	1.4	4
39	Role of ABC and Solute Carrier Transporters in the Placental Transport of Lamivudine. Antimicrobial Agents and Chemotherapy, 2016, 60, 5563-5572.	1.4	19
40	The Nonmetabolized Î²-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3. Molecular Pharmaceutics, 2016, 13, 512-519.	2.3	33
41	Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients. PLoS ONE, 2016, 11, e0155649.	1.1	42
42	Renal tubular secretion of pramipexole. European Journal of Pharmaceutical Sciences, 2015, 79, 73-78.	1.9	15
43	Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates. PLoS ONE, 2015, 10, e0136451.	1.1	92
44	Inhibitory Effects of Green Tea and (â€“)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein. PLoS ONE, 2015, 10, e0139370.	1.1	64
45	Interplay between the prostaglandin transporter OATP2A1 and prostaglandin E2-mediated cellular effects. Cellular Signalling, 2015, 27, 663-672.	1.7	3
46	N1-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metforminâ€“trimethoprim interaction. European Journal of Clinical Pharmacology, 2015, 71, 85-94.	0.8	79
47	Alanine-glyoxylate aminotransferase 2 (AGXT2) Polymorphisms Have Considerable Impact on Methylarginine and Î²-aminoisobutyrate Metabolism in Healthy Volunteers. PLoS ONE, 2014, 9, e88544.	1.1	33
48	Organic anion transporting polypeptides and organic cation transporter 1 contribute to the cellular uptake of the flavonoid quercetin. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 883-891.	1.4	37
49	Implementation of Warnings From Dear Doctor Letters (Rote-Hand-Briefe). Deutsches Ärzteblatt International, 2014, 111, 255-63.	0.6	23
50	The effect object paradigm--a means to support medication safety with clinical decision support. Studies in Health Technology and Informatics, 2014, 205, 1065-9.	0.2	3
51	Potentially inappropriate medications in a large cohort of patients in geriatric units: association with clinical and functional characteristics. European Journal of Clinical Pharmacology, 2013, 69, 975-984.	0.8	20
52	Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochemical Pharmacology, 2013, 86, 808-815.	2.0	85
53	Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects. Pharmacological Reviews, 2013, 65, 944-966.	7.1	475
54	Clinical relevance of drug efflux pumps in the gut. Current Opinion in Pharmacology, 2013, 13, 847-852.	1.7	44

#	Article	IF	Citations
55	Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1). Amino Acids, 2013, 45, 989-1002.	1.2	41
56	Transporter Gene Expression in Human Head and Neck Squamous Cell Carcinoma and Associated Epigenetic Regulatory Mechanisms. American Journal of Pathology, 2013, 182, 234-243.	1.9	9
57	Different indications, warnings and precautions, and contraindications for the same drugâ€"an international comparison of prescribing information for commonly used psychiatric drugs. Pharmacoepidemiology and Drug Safety, 2013, 22, 329-333.	0.9	18
58	Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1). Journal of Molecular and Cellular Cardiology, 2012, 53, 392-400.	0.9	52
59	Inhibition of hepatic uptake transporters by flavonoids. European Journal of Pharmaceutical Sciences, 2012, 46, 79-85.	1.9	59
60	Characterization of Ursodeoxycholic and Norursodeoxycholic Acid as Substrates of the Hepatic Uptake Transporters <scp>OATP</scp>1B1, <scp>OATP</scp>1B3, <scp>OATP</scp>2B1 and <scp>NTCP</scp>. Basic and Clinical Pharmacology and Toxicology, 2012, 111, 81-86.	1.2	24
61	Effect of the rs168924 Singleâ€Nucleotide Polymorphism in the SLC6A2 Catecholamine Transporter Gene on Blood Pressure in Caucasians. Journal of Clinical Hypertension, 2012, 14, 293-298.	1.0	10
62	Deletion of the Mammalian INDY Homolog Mimics Aspects of Dietary Restriction and Protects against Adiposity and Insulin Resistance in Mice. Cell Metabolism, 2011, 14, 184-195.	7.2	193
63	Transporter-Mediated Drugâ€"Drug Interactions with Oral Antidiabetic Drugs. Pharmaceutics, 2011, 3, 680-705.	2.0	29
64	Organic Cation Transporter 3: Expression in Failing and Nonfailing Human Heart and Functional Characterization. Journal of Cardiovascular Pharmacology, 2011, 58, 409-417.	0.8	32
65	The Role of ABCC Family Members in the Disposition of Endogenous Compounds and Drugs. , 2011, , 209-245.		0
66	Paraoxonase-1 Q192R Polymorphism and Antiplatelet Effects of Clopidogrel in Patients Undergoing Elective Coronary Stent Placement. Circulation: Cardiovascular Genetics, 2011, 4, 429-436.	5.1	91
67	Transporter-mediated drugâ€"drug interactions. Pharmacogenomics, 2011, 12, 1017-1037.	0.6	148
68	Expression and localization of the uptake transporters OATP2B1, OATP3A1 and OATP5A1 in non-malignant and malignant breast tissue. Cancer Biology and Therapy, 2011, 11, 584-591.	1.5	54
69	Molecular Mechanism of Renal Tubular Secretion of the Antimalarial Drug Chloroquine. Antimicrobial Agents and Chemotherapy, 2011, 55, 3091-3098.	1.4	64
70	Influence of Non-Steroidal Anti-Inflammatory Drugs on Organic Anion Transporting Polypeptide (OATP) 1B1- and OATP1B3-Mediated Drug Transport. Drug Metabolism and Disposition, 2011, 39, 1047-1053.	1.7	94
71	Role of Organic Anion-Transporting Polypeptides for Cellular Mesalazine (5-Aminosalicylic Acid) Uptake. Drug Metabolism and Disposition, 2011, 39, 1097-1102.	1.7	40
72	Functional and Structural Relevance of Conserved Positively Charged Lysine Residues in Organic Anion Transporting Polypeptide 1B3. Molecular Pharmacology, 2011, 80, 400-406.	1.0	24

#	Article	IF	Citations
73	Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochemical Pharmacology, 2010, 80, 1746-1753.	2.0	121
74	Gender Is an Important Determinant of the Disposition of the Loop Diuretic Torasemide. Journal of Clinical Pharmacology, 2010, 50, 160-168.	1.0	49
75	SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics, 2010, 11, 1703-1713.	0.6	48
76	Influence of Cyclooxygenase Inhibitors on the Function of the Prostaglandin Transporter Organic Anion-Transporting Polypeptide 2A1 Expressed in Human Gastroduodenal Mucosa. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 345-351.	1.3	34
77	Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment With Clopidogrel in Patients Undergoing Elective Coronary Stent Placement. Journal of the American College of Cardiology, 2010, 55, 2427-2434.	1.2	285
78	Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects. Drug Metabolism Reviews, 2010, 42, 380-401.	1.5	93
79	Drug transport by breast cancer resistance protein. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1363-1384.	1.5	23
80	Functional Characterization of the Human Organic Cation Transporter 2 Variant p.270Ala>Ser. Drug Metabolism and Disposition, 2009, 37, 1312-1318.	1.7	80
81	Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379, 337-348.	1.4	101
82	In vitroevidence for the role of OATP and OCT uptake transporters in drugâ€“drug interactions. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 489-500.	1.5	71
83	ATP-binding cassette transporters in human heart failure. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 377, 231-243.	1.4	45
84	The association of ABCB1 polymorphisms and elevated serum digitoxin concentrations in geriatric patients. European Journal of Clinical Pharmacology, 2008, 64, 367-372.	0.8	0
85	6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4. Human Mutation, 2008, 29, 659-669.	1.1	46
86	Animal models and intestinal drug transport. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 347-361.	1.5	21
87	Determinants of Steady-State Torasemide Pharmacokinetics. Clinical Pharmacokinetics, 2008, 47, 323-332.	1.6	37
88	Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents. Journal of the American College of Cardiology, 2008, 51, 1925-1934.	1.2	523
89	Activation of negative regulators of the hypoxia-inducible factor (HIF) pathway in human end-stage heart failure. Biochemical and Biophysical Research Communications, 2008, 376, 315-320.	1.0	50
90	Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters. Diabetes, 2008, 57, 1463-1469.	0.3	111

#	Article	IF	Citations
91	The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 51-64.	1.5	44
92	Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenetics and Genomics, 2008, 18, 559-568.	0.7	87
93	The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3. Drug Metabolism and Disposition, 2007, 35, 779-786.	1.7	175
94	Functional analysis of the polymorphism â^'211C>T in the regulatory region of the human ABCC3 gene. Life Sciences, 2007, 80, 1490-1494.	2.0	27
95	Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. FASEB Journal, 2007, 21, 2343-2351.	0.2	114
96	Increased??Absorption??of??Digoxin from??the??Human??Jejunum Due??to??Inhibition??of??Intestinal Transporter-Mediated Efflux. Clinical Pharmacokinetics, 2007, 46, 777-785.	1.6	64
97	Role of P-Glycoprotein Inhibition forÂDrug Interactions. Clinical Pharmacokinetics, 2007, 46, 1039-1049.	1.6	101
98	Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation. European Journal of Clinical Pharmacology, 2007, 63, 1129-1133.	0.8	13
99	Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein1. Fundamental and Clinical Pharmacology, 2006, 20, 273-282.	1.0	75
100	Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4â€"dependent pharmacokinetics in humans. Clinical Pharmacology and Therapeutics, 2006, 79, 449-460.	2.3	16
101	Pharmacogenomics of human OATP transporters. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 372, 432-443.	1.4	308
102	ATP-Binding Cassette Transporters in the Heart. Trends in Cardiovascular Medicine, 2006, 16, 7-15.	2.3	44
103	CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenetics and Genomics, 2005, 15, 737-741.	0.7	26
104	Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clinical Pharmacology and Therapeutics, 2005, 77, 291-301.	2.3	138
105	Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding) Tj ETQq1 1 0.784314 rgBT /Ov	1.1	134
106	Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography. Biomedical Chromatography, 2005, 19, 777-782.	0.8	15
107	Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein. Naunyn-Schmiedeberg's Archives of Pharmacology, 2005, 371, 195-201.	1.4	19
108	Antimalarial Artemisinin Drugs Induce Cytochrome P450 and MDR1 Expression by Activation of Xenosensors Pregnane X Receptor and Constitutive Androstane Receptor. Molecular Pharmacology, 2005, 67, 1954-1965.	1.0	206

#	Article	IF	Citations
109	CYP3A5 Genotype is Associated with Diagnosis of Hypertension in Elderly Patients. Molecular Diagnosis and Therapy, 2005, 5, 191-195.	3.3	36
110	Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundamental and Clinical Pharmacology, 2004, 18, 621-626.	1.0	108
111	Identification of Budesonide and Prednisone as Substrates of the Intestinal Drug Efflux Pump P-glycoprotein. Inflammatory Bowel Diseases, 2004, 10, 578-583.	0.9	78
112	Effect of amiodarone on the plasma levels of metoprolol. American Journal of Cardiology, 2004, 94, 1319-1321.	0.7	37
113	Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 370, 124-30.	1.4	29
114	Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clinical Pharmacology and Therapeutics, 2004, 75, 172-183.	2.3	230
115	Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. Clinical Pharmacology and Therapeutics, 2004, 76, 230-238.	2.3	24
116	Importance of P-glycoprotein at bloodâ€“tissue barriers. Trends in Pharmacological Sciences, 2004, 25, 423-429.	4.0	481
117	High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics and Genomics, 2004, 14, 429-440.	5.7	391
118	Clinical Aspects of the MDR1 (ABCB1) Gene Polymorphism. Therapeutic Drug Monitoring, 2004, 26, 180-185.	1.0	170
119	P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clinical Pharmacology and Therapeutics, 2003, 73, 223-231.	2.3	139
120	GENETICPOLYMORPHISMS OF THEHUMANMDR1DRUGTRANSPORTER. Annual Review of Pharmacology and Toxicology, 2003, 43, 285-307.	4.2	294
121	Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clinical Pharmacology and Therapeutics, 2003, 74, 130-137.	2.3	74
122	Pharmacokinetic Interactions with Rifampicin. Clinical Pharmacokinetics, 2003, 42, 819-850.	1.6	591
123	Influence of Omeprazole on Multidrug Resistance Protein 3 Expression in Human Liver. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 524-530.	1.3	46
124	Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine. Journal of Biological Chemistry, 2002, 277, 24280-24288.	1.6	164
125	Piperine, a Major Constituent of Black Pepper, Inhibits Human P-glycoprotein and CYP3A4. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 645-650.	1.3	421
126	The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Advanced Drug Delivery Reviews, 2002, 54, 1295-1310.	6.6	225

#	Article	IF	Citations
127	Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration. Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 366, 218-225.	1.4	7
128	MDR1gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. British Journal of Clinical Pharmacology, 2002, 53, 526-534.	1.1	226
129	Determination of fexofenadine in human plasma and urine by liquid chromatographyâ€“mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 766, 227-233.	1.2	51
130	Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. Clinical Pharmacology and Therapeutics, 2002, 71, 131-140.	2.3	41
131	Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clinical Pharmacology and Therapeutics, 2002, 72, 584-594.	2.3	279
132	Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 364, 551-557.	1.4	205
133	P-glycoprotein-mediated transport of digitoxin, Î±-methyldigoxin and Î²-acetyldigoxin. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 337-343.	1.4	43
134	Sympathetic Activation Enhances QT Prolongation by Quinidine. Journal of Cardiovascular Electrophysiology, 2001, 12, 9-14.	0.8	15
135	Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: An investigation comparing single and multiple dosing. Clinical Pharmacology and Therapeutics, 2001, 69, 324-332.	2.3	11
136	Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clinical Pharmacology and Therapeutics, 2001, 70, 217-227.	2.3	78
137	The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters. American Journal of Pathology, 2000, 157, 1575-1580.	1.9	269
138	Inhibition of P-Glycoproteinâ€“Mediated Drug Transport. Circulation, 1999, 99, 552-557.	1.6	407
139	Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmaceutical Research, 1999, 16, 408-414.	1.7	404
140	Gut wall metabolism of verapamil in older people: effects of rifampicinâ€•mediated enzyme induction. British Journal of Clinical Pharmacology, 1998, 45, 247-255.	1.1	52
141	Modulation by Dietary Salt of Verapamil Disposition in Humans. Circulation, 1998, 98, 2702-2708.	1.6	31
142	Loss of analgesic effect of morphine due to coadministration of rifampin. Pain, 1997, 72, 261-267.	2.0	90
143	Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. British Journal of Clinical Pharmacology, 1996, 42, 387-389.	1.1	81
144	Stereoselectivity in Drug Metabolism and Action: Effects of Enzyme Inhibition and Induction. Therapeutic Drug Monitoring, 1996, 18, 388-392.	1.0	18

#	Article	IF	Citations
145	Dihydrocodeine: A new opioid substrate for the polymorphic CYP2D6 in humans*. Clinical Pharmacology and Therapeutics, 1995, 58, 374-382.	2.3	63
146	Simultaneous determination of dihydrocodeine and dihydromorphine in serum by gas chromatography-tandem mass spectrometry. Biomedical Applications, 1995, 663, 59-65.	1.7	23